These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8942397)

  • 1. Normal insulin release during sustained hyperglycaemia in hypokalaemic periodic paralysis: role of the potassium channel opener pinacidil in impaired muscle strength.
    Ligtenberg JJ; Van Haeften TW; Van Der Kolk LE; Smit AJ; Sluiter WJ; Reitsma WD; Links TP
    Clin Sci (Lond); 1996 Nov; 91(5):583-9. PubMed ID: 8942397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium channels in hypokalaemic periodic paralysis: a key to the pathogenesis?
    Links TP; Smit AJ; Oosterhuis HJ; Reitsma WD
    Clin Sci (Lond); 1993 Sep; 85(3):319-25. PubMed ID: 8403805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension.
    Ligtenberg JJ; Leenaers AD; Van Haeften TW; Smit AJ; Sluiter WJ; Reitsma WD
    J Hum Hypertens; 1996 Apr; 10(4):269-76. PubMed ID: 8736460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phentolamine precludes inhibitory effect of the K+ channel opener pinacidil on insulin release.
    Links TP; Smit AJ; van Haeften TW; Reitsma WD
    Horm Metab Res; 1996 Jan; 28(1):20-2. PubMed ID: 8820989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of the vasodilator pinacidil on insulin secretion in healthy humans.
    Nielsen-Kudsk JE; Mellemkjaer S; Nielsen CB; Siggaard C
    J Clin Pharmacol; 1990 May; 30(5):409-11. PubMed ID: 2189901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium channel modulation: effect of pinacidil on insulin release in healthy volunteers.
    Links TP; Smit AJ; Reitsma WD
    J Clin Pharmacol; 1995 Mar; 35(3):291-4. PubMed ID: 7608319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pinacidil inhibits insulin release by increasing K+ outflow from pancreatic B-cells.
    Lebrun P; Devreux V; Hermann M; Herchuelz A
    Eur J Pharmacol; 1988 Nov; 156(2):283-6. PubMed ID: 3071468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment for periodic paralysis.
    Sansone V; Meola G; Links TP; Panzeri M; Rose MR
    Cochrane Database Syst Rev; 2008 Jan; (1):CD005045. PubMed ID: 18254068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperinsulinaemia in thyrotoxic hypokalaemic periodic paralysis.
    Lee KO; Taylor EA; Oh VM; Cheah JS; Aw SE
    Lancet; 1991 May; 337(8749):1063-4. PubMed ID: 1673496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis.
    Wu F; Mi W; Cannon SC
    Brain; 2013 Dec; 136(Pt 12):3766-74. PubMed ID: 24142145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin receptors, insulin secretion, and glucose disappearance rate in patients with periodic hypokalaemic paralysis.
    Johnsen T; Beck-Nielsen H
    Acta Endocrinol (Copenh); 1979 Feb; 90(2):272-82. PubMed ID: 419916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin modulation of ATP-sensitive K+ channel of rat skeletal muscle is impaired in the hypokalaemic state.
    Tricarico D; Capriulo R; Conte Camerino D
    Pflugers Arch; 1999 Jan; 437(2):235-40. PubMed ID: 9929564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cation transport across lymphocyte plasma membranes in euthyroid and thyrotoxic men with and without hypokalaemic periodic paralysis.
    Oh VM; Taylor EA; Yeo SH; Lee KO
    Clin Sci (Lond); 1990 Feb; 78(2):199-206. PubMed ID: 2155749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retigabine suppresses loss of force in mouse models of hypokalaemic periodic paralysis.
    Quiñonez M; DiFranco M; Wu F; Cannon SC
    Brain; 2023 Apr; 146(4):1554-1560. PubMed ID: 36718088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare case of unilateral adrenal hyperplasia accompanied by hypokalaemic periodic paralysis caused by a novel dominant mutation in CACNA1S: features and prognosis after adrenalectomy.
    Yang B; Yang Y; Tu W; Shen Y; Dong Q
    BMC Urol; 2014 Nov; 14():96. PubMed ID: 25430699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of glibenclamide on insulin release at moderate and high blood glucose levels in normal man.
    Ligtenberg JJ; Venker CE; Sluiter WJ; Reitsma WD; Van Haeften TW
    Eur J Clin Invest; 1997 Aug; 27(8):685-9. PubMed ID: 9279533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biophysical and pharmacological characteristics of skeletal muscle ATP-sensitive K+ channels are modified in K+-depleted rat, an animal model of hypokalemic periodic paralysis.
    Tricarico D; Pierno S; Mallamaci R; Brigiani GS; Capriulo R; Santoro G; Camerino DC
    Mol Pharmacol; 1998 Jul; 54(1):197-206. PubMed ID: 9658206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pinacidil, RP 49356 and nicorandil on ATP-sensitive potassium channels in insulin-secreting cells.
    Dunne MJ
    Br J Pharmacol; 1990 Mar; 99(3):487-92. PubMed ID: 2158844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoids may trigger attacks in several types of periodic paralysis.
    Arzel-Hézode M; McGoey S; Sternberg D; Vicart S; Eymard B; Fontaine B
    Neuromuscul Disord; 2009 Mar; 19(3):217-9. PubMed ID: 19201608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.